- Home
- FBRT vs GHRS Comparison
FBRT vs GHRS Comparison
Compare FBRT & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRT | GHRS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.8M | 947.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FBRT | GHRS |
|---|---|---|
| Price | $8.82 | $17.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $13.50 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 866.5K | 116.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.24 | $8.66 |
| 52 Week High | $11.86 | $19.51 |
Technical Indicators
Market Signals| Indicator | FBRT | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 68.13 |
| Support Level | $8.33 | $12.34 |
| Resistance Level | $9.23 | $19.26 |
| Average True Range (ATR) | 0.20 | 0.86 |
| MACD | 0.08 | 0.38 |
| Stochastic Oscillator | 82.14 | 85.89 |
Price Performance
Historical ComparisonAbout FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.